Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03579901

Study of the Safety and Effectiveness of Motiva Implants®

This study evaluates the safety and effectiveness Motiva Implants® in women who are undergoing primary breast augmentation, primary breast reconstruction or revision breast surgery.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Plastische Chirurgie im Medienhafen, Düsseldorf, Germany

Loading trial locations.

About this study

Prospective, Single Arm, Multicenter Study. Following FDA approval, follow-up data will continue to be collected for all cohorts on adverse events, reoperations, patient satisfaction, physician satisfaction and quality of life for a total of 10 years.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Genetic female.
  • Patient is seeking one of the following procedures:

Primary Breast Augmentation Primary Breast Reconstruction Revision Augmentation Revision Reconstruction

  • Patient has adequate tissue available to cover implant(s).
  • Willingness to follow all study requirements including agreeing to attend all required follow-up visits and signs the informed consent.
  • Agrees to have device returned to Establishment Labs if explanted.
  • Willing to undergo Magnetic Resonance Imaging (MRI) evaluation of medically advised.

Exclusion criteria

  • Has any breast disease considered to be pre-malignant in one or both breasts or is reporting mutations in BRCA1 or BRCA2 without a previous bilateral mastectomy or an untreated cancer of any type.
  • Has inadequate or unsuitable tissue (e.g., due to radiation damage, ulceration compromised vascularity, history of compromised wound healing).
  • Has an abscess or infection.
  • Is pregnant or nursing or has had a full-term pregnancy or lactated within 6 months of enrollment.
  • Is taking any drugs that would interfere with blood clotting, or that might result in elevated risk and or significant postoperative complications.
  • Has any medical condition such as obesity (BMI ≥ 40), diabetes, autoimmune disease, chronic lung or severe cardiovascular disease that might result in unduly high surgical risk and or significant postoperative complications.
  • Has any connective tissue/autoimmune disorder or rheumatoid disease, such as systemic lupus erythematosus, discoid lupus, scleroderma, or rheumatoid arthritis, among others.
  • Has any condition that impedes the use of magnetic resonance imaging (MRI) including implanted metal device, claustrophobia or other conditions that would make MRI scan prohibited.
  • Has a history of psychological characteristics that are unrealistic or unreasonable given the risks involved with the surgical procedure.
  • Has been implanted with any non-FDA approved breast implant.
  • Has been implanted with any silicone implant other than breast implants.
  • HIV positive (based on medical history).
  • Has been diagnosed with anaplastic large cell lymphoma (ALCL).
  • Works for Establishment Labs, Motiva USA or any of their subsidiaries, the study surgeon, or ICON the Contract Research Organization (CRO) that is helping to conduct the study or are directly-related to anyone that works for Establishment Labs, Motiva USA or any of their subsidiaries, the study surgeon, or the CRO.

Treatment and study plan

Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants

Device

Breast augmentation

Primary outcomes

  1. Analyze and report the total adverse events rate ("any complication)" of the Silicone Gel filled Motiva Implants®. Kaplan-Meier analysis of adverse events will be conducted by time period for each type of adverse event.

    Time frame: 10 Years

  2. Analyze patient satisfaction on a 5-point Likert scale post-implant for all implantation groups.

    Time frame: 10 Years

Secondary outcomes

  1. Kaplan-Meier analysis of all complications, including reoperation and explantation

    Time frame: 10 Years

  2. Cox regression analyses for the following endpoints: Capsular contracture III/IV, Breast Pain, Infection, and Implant Rupture

    Time frame: 10 Years

  3. Kaplan-Meier analysis of rupture.

    Time frame: 10 Years

  4. Kaplan-Meier analysis of connective tissue disease (CTD) and CTD signs/symptoms

    Time frame: 10 Years

  5. Kaplan-Meier analysis of Cancer (Breast Cancer, Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), and others)

    Time frame: 10 Years

  6. Patient Satisfaction with Breast (BREAST-Q™) Questionnaire

    Time frame: 10 Years

  7. Physician Satisfaction (5-point Likert scale)

    Time frame: 10 Years

  8. Validated Quality of Life questionnaires

    Time frame: 10 Years

  9. Breast Measurements (Net Chest Circumference and Hemi-Circumference) change from baseline

    Time frame: 10 Years

Sponsors and collaborators

Lead sponsor

Motiva USA LLC

Industry

Registry information

Official study title

Study of the Safety and Effectiveness of the Motiva Implants® Silicone Gel-Filled Breast Implants SmoothSilk® in Subjects Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction, and Revision Surgery

Important dates

Study start
2018
Primary completion
2032
Study completion
2033
First posted
Jul 9, 2018
Registry last updated
Nov 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.